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ABSTRACT
Gastric motility disorder or gastroparesis is an objective slowing of gastrointestinal emptying syndrome, 
in the absence of mechanical obstruction, with cardinal symptoms such as rapid feeling of fullness, fullness 
sensation after eating, nausea, vomiting, bloating, and upper abdominal pain. Patients with gastroparesis are 
at risk of weight loss, malnutrition, and lack of vitamins and minerals, as well as increasing morbidity and 
mortality. The prevalence and incidence data of gastroparesis do not describe the true reality, because of the 
complexity of diagnosis. Beside Diabetes mellitus, many other causes should also be considered. Several studies 
have shown that nausea, vomiting and fullness sensation in abdominal are the most associated symptoms with 
gastroparesis. A 4-hour solid phase gastric emptying scintigraphy is the diagnostic standard for the slowing 
of gastric emptying. Lowest effective dose metoclopramide starting with a dose of 3 x 5 mg is the first line 
for pharmacological therapy. For persistent or refractory gastroparesis with pharmacologic therapy, gastric 
electrical stimulation (GES) and surgical therapy may be considered. The management should involve relevant 
medical team by not forget to consider patient comfort.
Kata kunci: impaired gastric motility, gastroparesis, slowing of gastric emptying
ABSTRAK
Gangguan motilitas lambung atau gastroparesis adalah sindrom perlambatan pengosongan lambung secara 
obyektif, tanpa adanya obstruksi mekanis, dengan gejala kardinal seperti cepat merasa kenyang, rasa penuh 
setelah makan, mual, muntah, kembung, dan nyeri perut bagian atas. Pasien dengan gastroparesis berisiko 
mengalami penurunan berat badan, kekurangan gizi, dan kekurangan vitamin dan mineral, serta meningkatkan 
morbiditas dan mortalitas. Data prevalensi dan insidensi dari gastroparesis tidak menggambarkan realita 
sesungguhnya, karena cukup rumitnya penegakan diagnosis. Tidak hanya Diabetes mellitus, banyak penyebab 
lain juga harus dipikirkan. Beberapa studi menunjukkan mual muntah dan rasa penuh pada perut merupakan 
gejala yang paling berkaitan dengan gastroparesis. Pemeriksaan skintigrafi pengosongan lambung fase padat 
selama 4 jam merupakan standar baku untuk diagnostik perlambatan pengosongan lambung. Metoclopramide 
dosis efektif terendah dimulai dengan dosis 3 x 5 mg merupakan lini pertama untuk terapi farmakologis. Untuk 
gastroparesis persisten atau refrakter dengan terapi farmakologis dapat dipertimbangkan gastric electrical 
stimulation (GES) dan terapi pembedahan. Tata laksana harus melibatkan tim medis terkait dengan tidak lupa 
mempertimbangkan kenyamanan pasien.
Kata kunci: gangguan motilitas lambung, gastroparesis, perlambatan pengosongan lambung
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INTRODUCTION
Gastric motility disorder including gastroparesis are 
chronic abdominal motility abnormalities characterized 
by a slowing of gastric emptying.1 Symptoms include 
rapid feeling of fullness, fullness sensation after eating, 
abdominal distension, nausea, and vomiting. Patients 
with gastroparesis may have eating-related symptoms, 
resulting in reluctance to eat and inadequate oral 
intake. Some patients experience prolonged nausea and 
vomiting, which make it difficult to maintain hydration 
and nutritional status. Thus, patients with gastroparesis 
are at risk of weight loss, malnutrition, and deficiencies 
of vitamins and minerals.2
Gastroparesis significantly affects quality of life, 
increases health care costs through inpatient care, 
emergency room, or physician visits, and is associated 
with morbidity and mortality.3 Based on data in the 
United States Medicare on hospitalization related to 
gastroparesis in the United States from 1995 to 2004, 
it showed that hospitalization for gastroparesis has 
increased since 2000.4
Studies by Hyett et al regarding the slowing of 
gastric emptying predict negative health outcomes 
in diabetic patients with gastroparesis symptom. In 
this study, it was found that diabetic patients with 
gastroparesis complications used a significantly greater 
amount of health resources than non-gastroparesis 
diabetic patients. There are significant differences in 
the amount of health care usage, including inpatient 
rates, outpatient visits, sick days, ED visits, and 
frequency of treatments.5 Gastrointestinal symptoms 
negatively affected health-related quality of life in 
patients with diabetes mellitus.6
DEFINITION
Normal or peristaltic motility is ordered regular 
muscle contraction from top to bottom. Functional 
dyspepsia (non-ulcer dyspepsia): Abnormal gastric 
accommodation reflex or decreased fundal relaxation 
may lead to functional dyspepsia. The patients’ 
symptoms are including pain or discomfort and 
bloating in the upper abdomen, fullness and nausea.7 
Gastroparesis is defined as objective slowing of 
gastrointestinal emptying syndrome in the absence 
of mechanical obstruction and cardinal symptoms 
including rapid feeling of fullness, fullness sensation 
after eating, nausea, vomiting, bloating, and upper 
abdominal pain.3
EPIDEMIOLOGY
The high prevalence of gastroparesis have been 
reported in patients with type 1 diabetes (40%) and 
type 2 diabetics (10-20%). The study came from a 
tertiary academic medical center where the prevalence 
is estimated to be higher than the general population. 
Prevalence in the community is estimated to be ~ 5% 
among type 1 diabetics and 1% among type 2 diabetics.3 
On January 1st 2007, the means of age-adjusted 
prevalence of gastroparesis per 100,000 people were 
24.2 (95% CI: 15.7-32.6) for both sexes, 9.6 (95% CI: 
1.8-17.4) for men, and 37.8 (95% CI: 23.3-52.4) for 
women. The incidence rates corresponding for 1996-
2006 were 2.4 (95% CI: 1.2-3.8) for men and 9.8 (95% 
CI: 7.5-12.1) for women.4
PATHOPHYSIOLOGY
Gastroduodenal motility disorder consists of 
impaired gastric accomodation, antroduodenal 
incoordination, and slowing of gastric emptying. 
Gastroduodenal motility disorder is one of the major 
mechanisms in the pathophysiology of functional 
dyspepsia, related to fullness sensation after eating, 
which may be abdominal distension, bloating, and 
fullness.8
Abnormal motility of the upper gastrointestinal tract 
involves functional abnormalities in the esophagus, 
stomach, and small intestine. There are three main 
components of functional gastrointestinal disorder: 
gastrointestinal motility or contraction, gastrointestinal 
tract sensations, and gastrointestinal brain dysfunction, 
all of which affect upper and lower gastrointestinal 
tract.7
In gastrointestinal functional disorder, muscle 
spasms can cause pain, or contractions could be very 
rapid or very slow, altering the speed or direction of 
gastrointestinal transit. Gastric nerves are sometimes 
so sensitive that even normal contractions can cause 
pain or discomfort in response to physiological stimuli, 
such as digesting food. The regulatory relationship 
between brain function and the gastrointestinal tract 
might be disrupted, causing disharmony in the way 
the brain and gastrointestinal systems communicate, 
altering the transit of luminal contents.7
RISK FACTORS
Diabetes (29%), postoperative (13%), and 
idiopathic (36%) are the etiologies of most cases in 
tertiary referrals.1 Diabetes accounts for about one-
Volume 19, Number 1, April 2018 27
Management of Gastric Motility Disorder
third of all cases.5 Longitudinal studies showed that 
the gastric emptying clearance encountered in 25-
55% of patients with type 1 diabetes and about 30% 
of patients with diabetes type 2.9 However, the real 
prevalence is unknown.5 Furthermore, at least until 
some patients with long-standing diabetes, suffering 
from gastroparesis, remain mostly subclinical.9
In patients with refractory symptoms of 
gastroesophageal reflux disease (GERD), slowing of 
gastric emptying examination should be considered, 
as delayed gastric emptying may be associated with 
GERD and may exacerbate symptoms of ulcer disease, 
regurgitation, and other symptoms associated with 
GERD.3
ETIOLOGY
Idiopathic Gastroparesis
Patients with symtopm of undetected slowing of 
gastric empting, the primary abnormalities underlie 
the abnormal slowing of gastric emptying. This might 
be the most common form of gastroparesis. Most 
patients with idiopathic gastroparesis are women; 
usually young or middle aged. Symptoms of idiopathic 
gastroparesis overlap with functional dyspepsia; it may 
be difficult to give definitive differences between the 
two on the basis of symptoms, and many consider 
idiopathic gastroparesis and functional dyspepsia with 
slowing of gastric emptying as the same condition. 
Abdominal pain/discomfort is usually the main 
symptom of functional dyspepsia, whereas nausea, 
vomiting, full satiety, and bloating predominate in 
idiopathic gastroparesis. Therefore, the measurement 
of gastric emptying is very important, because therapy 
is different wheter gastric emptying is slow, normal, 
or fast.3
Postoperative Gastroparesis
Postoperative gastroparesis, often accompanied 
by vagotomy or vagal nerve injury, is the third 
most common etiology of gastroparesis. In the past, 
most cases originated from vagotomy performed in 
conjunction with gastric drainage to improve refractory 
or medically complicated peptic ulcers. Since the 
advent of laparoscopic techniques for the treatment of 
GERD, gastroparesis has been a known complication 
of fundoplication (possibly due to vagal injury during 
surgery) or bariatric surgery included in gastroplasty 
or bypass procedures.3
Post-viral Infection Gastroparesis
Some patients with gastroparesis reported sudden 
onset of symptoms after viral prodromal symptoms, 
suggesting a possible viral etiology for their symptoms, 
and diagnosis of post-viral gastroparesis. Healthy 
subject has experienced sudden onset of nausea, 
vomiting, diarrhea, fever, and cramps which indicate 
systemic viral infections. However, instead of 
experiencing symptoms improvement, the individual 
is still experiencing persistent nausea, vomiting, and 
satiety. In general, the course of this disease is typical 
of post-viral gastroparesis which is not associated with 
autonomic neuropathy.3
On the other hand, a small proportion of patients 
with viral infections such as cytomegalo, Epstein 
Barr, and varicella zoster may develop into autonomic 
neuropathy (generalized or selective cholinergic 
disautonomia) that includes gastroparesis. Patients 
with this autonomic dysfunction may have a slower 
resolution of symptoms which may take several years 
and the prognosis is worse than post-viral gastroparesis 
without autonomic disorders.3
Iatrogenic Gastroparesis
In addition to postoperative gastroparesis, other 
forms of iatrogenic gastroparesis are gastroparesis 
induced by pharmacological agents such as narcotic 
opiate analgesics, anticholinergic agents, and some 
diabetes drugs. Administration of μ-opiate receptor 
agonists causes a slowing of gastric emptying and 
may also cause nausea and vomiting. This group 
includes agents such as morphine, as well as oxycodone 
and tapentadol, but less with tramadol. Therefore, 
patients receiving the drug should first undergo 
drug discontinuation before assuming a diagnosis of 
gastroparesis.3
GLP-1 analogue, like exenatide, used for the 
treatment of type 2 diabetes mellitus can slow 
gastric emptying. Unlike the GLP-1 analogue, which 
substantially increases plasma GLP-1 concentrations, 
dipeptidyl peptidase IV inhibitors, which increases 
plasma GLP-1 concentrations by inhibiting GLP-1 
metabolism, does not slow gastric emptying.3
Antirejection drugs, cyclosporine, can slow gastric 
emptying. Thus, in patients with previous transplants 
treated with antirejection treatment with cyclosporine, 
there may be a slowing of gastric emptying. This does 
not apply to other calcineurin inhibitors, tacrolimus, 
derived from macrolide molecules and retains 
prokinetic properties.3
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Other Rare Etiologies
Other rare causes of gastroparesis include diseases 
which affect extrinsic neural control (such as 
Parkinsonism, amyloidosis, and paraneoplastic disease) 
or disorders that result in infiltration or degeneration of 
the muscle lining of the stomach (such as scleroderma). 
Mesenteric ischemia should also be considered a rare 
cause of possibly reversible gastroparesis.3
SIGNS AND SYMPTOMS
Various symptoms of dyspepsia are common in 
patients with gastroparesis, such as nausea, vomiting, 
upper abdominal pain, abdominal distension and 
bloating. Individual symptoms generally have a low 
specificity to predict the delay in empyting. Flatulence 
has been reported to be significantly correlated with 
delayed emptying of diabetic gastroparesis. In another 
study, fullness after-meal was statistically associated 
with a slowing of gastric emptying. When gastroparesis 
is associated with weight loss and patients need 
nutritional support to maintain weight, it is considered 
a more severe form of gastroparesis.10
Abdominal pain is a symptom that is often 
overlooked in gastroparesis. In a multicentre study 
of the NIH consortium on gastroparesis, 72% of 
gastroparesis patients had abdominal pain, but were the 
dominant symptom in only 18% of patients, reflecting 
the heterogeneous population of patients in this group. 
A tertiary referral study showed that abdominal pain 
was reported in 90% of 68 patients with a slowing 
of gastric emptying. Pain induced by eating (72%), 
occurred at night (74%), and disturbed sleep (66%). 
The severity of abdominal pain is in the same range as 
other symptoms (such as fullness sensation, bloating, 
and nausea) and is not correlated with the level of 
gastric emptying, but is associated with decreased 
quality of life.3
Objectively, patients with abdominal symptoms 
significantly interfere with their quality of life, but 
there is no correlation between their symptoms and 
the level of gastric emptying. Future research should 
aim to investigate not only gastric emptying but also 
gastric accommodation and visceral hypersensitivity, 
as not all symptoms can be explained by the slowing of 
gastric emptying.11 Female gender, relevant and severe 
fullness sensation after eating, and severe vomiting 
are independently associated with slowing of gastric 
emptying in patients with functional dyspepsia.12 The 
presence of anxiety or depression has been associated 
with more severe symptoms.3
DIAGNOSIS
There are three tests that can objectively demonstrate 
slowing of gastric emptying: scintigraphy, wireless 
motility capsule (WMC), and breath test. For all types 
of gastric emptying tests, patients should discontinue 
treatment that may affect gastric emptying. Both 
drugs which slow and accelerate gastric emptying 
should be discontinue, so that the tests do not give 
wrong results. Most drugs take time about 48-72 
hours. Hyperglycemia (glucose levels > 200 mg/dL) 
may slow gastric emptying in diabetic patients. It is 
advisable to delay testing of gastric emptying until 
relative euglycemia levels (blood glucose < 275 mg/
dL) is achieved in diabetics to obtain reliable emptying 
parameters in the absence of acute metabolic disorders.3
Scintigraphy
Gastric emptying scintigraphy from solid-phase 
foods is considered a standard for the diagnosis 
of gastroparesis, as it measures the emptying of 
physiologic calorie foods. For solid phase testing, most 
centers use egg sandwiches labeled 99m Tc colloid as 
test food, with standard imaging at time of 0, 1, 2, and 
4 hours. A 4-hour test of gastric emptying scintigraphy 
using EggBeaters (ConAgra Foods Inc., Omaha, NE, 
USA) with jam, toast and water is recommended by 
the Society of Nuclear Medicine and the American 
Neurogastroenterology and Motility Society.3
Assessment of gastric emptying for 4 hours is 
necessary. Emptying of solid foods with shorter 
duration or emptying of a single liquid food with 
scintigraphy, is associated with lower diagnostic 
sensitivity. The most reliable parameter for reporting 
gastric emptying is gastric retention at 4 hours. 
However, it is also important to assess the emptying 
at least 1 and 2 hours after the consumption of food 
with radiolabel, since elongation of the initial phase 
of emptying can also be attributed to the symptoms of 
gastroparesis, although retention of the stomach at 4 
hours is normal or slightly slowed.3
Wireless Motility Capsule (WMC)
WMCs which measure pH, pressure, and 
temperature can assess gastric emptying by measuring 
the transit time of the stomach acid of the capsule. 
Gastric emptying is determined when there is a rapid 
increase in pH which indicates the emptying of the 
acidic to the basic duodenal acids. The transit time 
in the stomach of the WMC (e.g., SmartPill, Given 
Imaging, Yoqneam, Israel) has an 85% high correlation 
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with T-90% gastric emptying scintigraphy (which is 
when there are only 10% of food left in the stomach), 
indicating that the transit time of the WMC represents 
the time towards the end of solid food emptying. The 
overall correlation between gastric emptying at WMC 
and gastric emptying at 4 hours with scintigraphy is 
0.73. 5-hour gastric transit time of WMC is the best 
way to differentiate subjects with normal or slow 
gastric emptying based on skintigraphy performed 
concurrently with 83% sensitivity and 83% specificity.3
Breath Test
Breath test has been used in clinical research to 
determine gastric emptying. This breath test using 13 
C-octanoate or -spirulina gives reproducible results that 
correlate with results in gastric emptying scintigraphy, 
including response to pharmacologic therapy.3
Electrogastrogram (EGG)
EGG is a diagnostic tool used to measure electrical 
control of gastric contractions. EGG often identifies 
the presence of dysrhythmias, particularly after meals, 
in patients with gastroparesis, chronic dyspepsia, 
anorexia nervosa and bulimia, cyclic vomiting 
syndrome, and other conditions characterized by 
slowing of gastric emptying. Dysrhythmias can be 
caused by abnormalities of the specialized muscle 
conduction system present in the stomach.7
EGG is similar to the electrocardiogram (EKG) 
of the heart, the EGG recording electrical signals that 
travel through the abdominal muscles that control 
muscle contraction. In addition, the EGG measures 
the neural activity of the stomach wall before and after 
food consumption, as well as conduction and coupling 
between muscle cells. The new EGG system records 
on four channels simultaneously, allowing complete 
collection of activity data over a short period of time.7
EGG is a non-invasive test, relatively inexpensive, 
and easy to do. Electrodes are placed on the abdominal 
skin above the stomach. While the patient is lying 
down, the electrodes record the electrical activity of 
the stomach. Initially, gastric activity is recorded after 
fasting, then again after a small meal. Sometimes 
EGG is performed simultaneously with or after gastric 
emptying study to diagnose and manage functional 
dyspepsia and idiopathic gastroparesis. By using 
computer analysis, the electric current power of the 
gastric muscle is measured. In normal gastric muscles, 
a regular electric rhythm produces an increase in the 
current after a meal. In people with irregular muscles 
or nerves, the electrical rhythm after an irregular meal 
or a voltage does not increase.7
Barostat Studies
Barostat studies measure the tone and stretching 
of the esophagus and upper stomach. It also measures 
gastric accommodation and stomach sensation. Barorat 
studies can show whether the upper stomach relaxes 
adequately during meals and how much stomach filling 
is needed to cause pain or discomfort. The intra-gastric 
balloon measures the resistance and volume changes. 
In some patients, barostat is used to diagnose GERD 
and GERD conditions which may be caused by altered 
esophageal and abdominal pressures. The advantage 
of baroque for gastrointestinal examination is close 
contact with the abdominal wall. The manometric test 
can accurately detect abdominal wall contractions in 
the esophagus, pylorus and small intestine. But it does 
not accurately measure gastrointestinal tone.7
Manometry
The pylorus manometry can measure the pyloric 
pressure by using water-perfused Dent Sleeve or 
e-sleeve from a high-resolution manometric system. 
The contribution of pylorus to gastric emptying 
disorders can be measured and treated promptly. 
Antroduodenal manometry measures pressure waves 
in the stomach and adjacent small intestine before and 
after physiological stimuli (eg food, erythromycin), and 
notes changes in antrum and duodenum pressure so that 
it can give information about how well the muscles and 
nerves in the stomach and small intestine work. The 
manometric catheter is placed in the stomach and small 
intestine. Catheter records muscle signals and pressure 
changes in fasting states and also when food or fluids 
are digested. Antroduodenal manometry notes muscle 
contraction and initiation site, propagation direction, 
frequency, and duration.7
Differential Diagnosis
Secondary gastritis due to Helicobacter pylori 
infection, peptic ulcer, and functional dyspepsia are 
some of the differential diagnoses of gastroparesis. 
Because rapid gastric emptying and functional 
dyspepsia may also occur with symptoms similar 
to gastroparesis, evidence of a retardation of gastric 
emptying is required before selecting therapy.3
Patients with unresolved vomiting may have 
gastroparesis rather than functional dyspepsia and 
should be investigated appropriately. We felt that a 
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solid phase 4-hours gastric emptying scan should 
be performed in functional dyspepsia patients with 
symptoms of predominantly severe nausea and 
vomiting which failed with empirical therapy.13 
Patients with functional dyspepsia with persistent 
nausea and vomiting may have marked gastric 
emptying retardation.14
The presence of rumination syndrome and/or eating 
disorders (including anorexia nervosa and bulimia) 
should be considered when evaluating gastroparesis 
patients. This disorder may be associated with a 
slowing of gastric emptying, and the identification of 
these disorders may alter management. Cyclic vomiting 
syndrome defined as episodic episodes of recurrent 
nausea and vomiting should also be considered during 
the patient's history taking. These patients may require 
other alternative therapies.3
CLINICAL APPROACH
The American Journal of Gastroenterology has 
given recommendation of step by step approach 
algorithm for the management of gastroparesis (Figure 
1 and 4).3
MANAGEMENT
Recent management of gastroparesis is unsatisfactory 
and this is an unmet need and an opportunity for the 
pharmaceutical industry to develop.15
Nutrition
Dietary management is often the first step in 
treating gastroparesis patients. Current dietary 
recommendations for gastroparesis patients include 
suggestions which compensate for the disturbance of 
gastric emptying by consuming low-fat and low-fibre 
meal, because fat and fiber can slow gastric emptying. 
To maintain caloric intake, it is recommended to eat in 
small quantities and often.16
In the study by Parkman et al, only 32% of patients 
received nutritional/dietary consultation after their 
gastroparesis diagnosis. This suggests that dietary 
history and treatment are often neglected in patients 
with gastroparesis. Nutrition consultation is more 
common in sicker and hospitalized patients. It is 
interesting that diabetic patients with gastroparesis 
tend to be less likely to have micronutrient deficiencies, 
this may reflect an increase in dietary education they 
Figure 1. Algorithm for diagnosis and management of patients with gastroparesis3
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receive. Multivariable logistic regression suggests 
that those who received prior nutritional counseling 
were more likely to meet their daily energy needs. 
Nutrition consultation by dietitians may be useful and 
should be considered in gastroparesis patients. Dietary 
compliance can be improved with multiple meetings 
rather than only single visits. This suggests dietary 
modification and nutrition consultation will improve 
patient intake with gastroparesis to reduce malnutrition 
and improve symptoms.2
Oral Nutrition
Foods with low fat content and low residuals should 
be recommended for gastroparesis patients, since fat 
and fiber tend to slow gastric emptying. Small meal 
size is recommended because the stomach is only 
able to empty about 1-2 kcal/minute. Therefore, small 
meal size, low fat and low fiber, with a frequency of 
4-5 times a day, suitable for gastroparesis patients. 
Increasing the liquid nutrient component of the diet 
should be recommended, since gastric emptying for 
fluids is often normal in patients with slowing of solid 
food emptying.3
In some patients, carbonated beverages, with 
the release of carbon dioxide, can worsen gastric 
distention; this type of intake should be minimized. 
Alcohol and smoking should be avoided as both can 
alter gastric emptying. In diabetic patients, control of 
near-normal sugar levels with diet and hypoglycemic 
drugs should be targeted, as improved blood sugar 
levels can accelerate gastric emptying.3
Enteral Nutrition
For patients with gastroparesis who can not 
maintain oral intake of nutrients, nutrition through 
jejunostomi tube, which passes through problemed 
stomach, can improve symptoms and reduce frequency 
of hospitalization. Placement of the jejunal feeding 
tube, if necessary for alimentation, should be preceded 
by successful nasojejunal feeding trials. Occasionally, 
bowel dysfunction can occur in gastroparesis patients 
causing intolerance to jejunal feeding. Enteral 
administration should always be preferred over 
parenteral nutrition for many practical reasons, such 
as cost, potential complications, and ease of giving.3
Blood Sugar Control
Gastroparesis may alter blood sugar control in 
diabetic patients, as slow gastric emptying lowers 
postprandial glucose peak and insulin requirements 
and increases the risk of postprandial hypoglycemia. 
According to study by Punkkinen et al, the rate of 
gastric emptying for solid foods is associated with 
autonomic neuropathy, but not with blood sugar 
control. To target optimal blood sugar control is 
essential in the prevention and treatment of diabetic 
gastroparesis, because good long-term blood sugar 
control will protect against the development of 
autonomic neuropathy.11
Acute hyperglycemia induced in experimental 
clinical studies has been shown to worsen gastric 
emptying or inhibit antral contractility, although its 
association with symptoms is unclear. The efficacy 
of long-term improvement in blood sugar control to 
normalization of gastric emptying and symptoms in 
diabetic patients is controversial. However, short-
term and long-term blood sugar control is indicated 
to increase long-term diabetes outcomes.3
Pharmacological Therapy
Metoclopramide
Metoclopramide, Dopamine-D2 receptor antagonist, 
is the only drug approved by the United States FDA for 
the treatment of gastroparesis not later than 12 weeks 
unless the patient has therapeutic benefits that exceed 
the potential risk.3 Metoclopramide may benefit both 
with central anti-vomitus effect as well as improve 
gastric emptying.15
The most common adverse extrapyramidal side 
effect of metoclopramide is acute dystonia (incidence 
rate 0.2%). A case series in the UK suggest the 
incidence of acute dystonia is higher in women, 
patients receiving higher doses, children, and young 
adults. While prolonged reactions are more common 
in elderly patients. Based on reports for 15 years, 
involuntary movements caused by metoclopramide 
about 95% were dystonia, 4% parkinsonism types, and 
1% tardive dyskinesia. This involuntary movement is 
more likely to appear after parenteral administration. 
The reaction of this dystonia can be treated with 
antihistamines (eg, 25-50 mg IV diphtheria, more than 
2 minutes), benzodiazepines (eg, diazepam 5-10 mg 
IV) or central anticholinergic agents (eg, benztropin 
1-4 mg IV to 6 mg / day). Metoclopramide may also 
be associated with a prolonged corrected QT interval.3
Recommendations on when and how to use 
metoclopramide for the treatment of gastroparesis in 
clinical practice include careful monitoring of patients 
for early signs of tardive dyskinesia (which can be 
overcome by early recognition and discontinuation 
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of therapy), use the lowest effective dose for each 
patient, starting with 3 x 5 mg before meals, use a liquid 
preparation to increase absorption and facilitation of 
dose titration to a maximum dose of 40 mg/day and 
use "drug holidays" or dose reduction (eg 5 mg, before 
two large meals a day) whenever clinically possible. 
Drug interactions may occur when administration of 
drugs that alter the function of cytochrome P450-2D6 
(CYP2D6).3
Domperidone
Domperidone is a type II dopamine antagonist 
similar to metoclopramide, which has equivalent 
efficacy but with lower central side effects. This drug 
effectively overcomes nausea and vomiting. The 
initial dose is 3 x 10 mg which can be increased to 
3 x 20 mg and before sleep. Given the domperidone 
tendency to prolong corrected QT intervals and 
rarely lead to cardiac arrhythmias, it is recommended 
that early electrocardiogram examination and after 
administration. This agent should be retained if 
corrected QT > 470 ms in men and > 450 ms in women. 
Domperidone can also cause an increase in prolactin 
levels and lead to lactation. Drug interactions may 
occur simultaneously with the administration of drugs 
that alter the function of CYP2D6. Drugs affecting 
CYP2D6 include antiemetics and antidepressants often 
given together in gastroparesis patients.3
Domperidone, does not cross the blood brain barrier 
as much as metoclopramide so it does not have the 
same neurological risk. However, this drug is not 
approved in the United States. Furthermore, even 
in countries where the drug is approved, the drug is 
spotlighted because of the risk of sudden death and 
cardiac arrhythmia associated with inhibition of hERG 
channel activity, which inhibits the rapid component 
of the cardiac delayed rectifier K (þ) current (I ( Kr)).15
Erythromycin
Erythromycin lactobionate is effective when 
administered IV at a dose of 3 mg/kg every 8 hours 
(through IV infusion for 45 minutes to avoid sclerosis 
veins), as shown in diabetic patients in hospital with 
gastroparesis. Many motilin agonists, including 
erythromycin, when given orally may improve 
gastric emptying and symptoms for several weeks, 
but with longer periods of administration often 
associated with tachyphylaxis due to downregulation 
of motilin receptors. Clinical response decreased after 
4 weeks of oral erythromycin administration, but 
some patients may continue to benefit. Erythromycin 
also undergoes drug interactions with agents that 
alter or are metabolized by CYP3A4. Erythromycin 
administration may also be associated with a corrected 
QT extension.3,15
Suggestions for the prokinetic dose are described 
in Figure 2. Clearly, there are specializations on this 
approach based on individual differences: The degree 
of malnutrition or weight loss, the rate of decreased 
gastric emptying (or gastric retention at 4 hours), and 
previous treatment response.3
5HT4 Receptor Agonist
Other agents that have been used for a long time are 
5HT4 receptor agonists, such as cisapride, mosapride, 
prucalopride, renzapride, sulpiride, zacopride. Initial 
agents in this class of drugs have side effects on the 
heart; newer 5-HT4 agonists with little or no adverse 
effects on the heart are currently being evaluated.15
Figure 2. Algorithm for prokinetic therapy in gastroparesis3
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Tricyclic Antidepressants (TCA)  
TCA may be considered for refractory nausea and 
vomiting in gastroparesis but will not improve gastric 
emptying and potentially inhibit gastric emptying. 
TCA in low doses may decrease symptoms of nausea, 
vomiting, and abdominal pain in gastroparesis. 
However, some TCA agents, such as amitriptyline, 
have anticholinergic effects and should be avoided 
in gastroparesis patients, as they slow down gastric 
emptying. Nortriptyline has a lower incidence of 
anticholinergic effects than amitriptyline. The 5-HT 
2 receptor antagonist, mirtazapine, has been reported 
to be effective for gastroparesis in one case report.3
Other Drugs
In addition to prokinetics, symptomatic treatment 
of these symptoms remains empirical and off-label for 
of nausea and vomiting non-specific indications, or 
emesis therapy induced by chemotherapy and palliative 
care. The most commonly prescribed antiemetic drugs 
are phenothiazines (including prochlorperazine and 
thiethylperazine) or antihistamine agents (including 
promethazine). There is no study comparing the 
efficacy of phenothiazines with newer antiemetics 
(such as the 5-HT3 serotonin receptor antagonist) for 
gastroparesis. There is no evidence that ondansetron 
is superior to metoclopramide and promethazine 
in reducing nausea in adults. The 5-HT 3 receptor 
antagonist is a reasonable second-line drug; neurokinin 
receptor antagonist, aprepitant, is effective in the 
treatment of severe vomiting and recurrent ketoacidosis 
episodes in diabetic patients.3
Synthetic cannabinoids, dronabinol, are also 
used in practice, but there is a risk of withdrawal 
hyperemesis, and the optimal treatment strategy is 
unclear. Transdermal scopolamine, which is effective 
for nausea associated with motion sickness, is used for 
nausea and vomiting of gastroparesis, although without 
peer-reviewed publication to support this practice. 
Among the alternative treatment therapies, acupuncture 
is the most studied method in the treatment of nausea 
and vomiting; one study reported a remarkable 
improvement in 94% of patients.1
Clinical guidelines and a summary of evidence 
on this and other therapies have been published in 
recent years and are summarized in Table 1. This 
table precedes the results of the NORIG trial, which 
fails to demonstrate the beneficial effects of low-dose 
nortriptyline in patients with idiopathic gastroparesis. 
This trial, however, is remarkable for low placebo 
response rates (23%) suggesting a general impression 
that high placebo level is a barrier to prove their 
effectiveness under these conditions.15
Table 1. Current approach to gastroparesis treatment15
Therapy Recommendation Level of evidence
Prokinetics Strong Moderate
Metoclopramide Moderate Moderate
Domperidone Moderate Moderate
Erythromycin Strong Moderate
Anti-vomitus Conditional Moderate
Tricyclic Conditional Low
Botulinum Toxin Strongly not 
recommended
High
Gastric electrical 
stimulation
Conditional Moderate
Injection of Intrapilorous botulinum Toxin
The manometric study of patients with diabetic 
gastroparesis showed prolonged period of increased 
pyloric tone and phasic contractions, a phenomenon 
known as "pyloric spasm". Botulinum toxin is a 
powerful neuromuscular transmission inhibitor. 
Several open label studies on a small number of 
patients with gastroparesis showed mild improvement 
of gastric emptying and symptoms for several months. 
Two double-blind, placebo-controlled studies have 
shown some improvement in gastric emptying, but no 
improvement in symptoms compared with placebo. 
If this therapy is effective, then the outcome of this 
treatment does not last long and repeat of procedures 
may be necessary. Long-term effects of repetition 
procedures have not been well studied. Thus, botulinum 
toxin injection into the pylorus is not recommended 
as a treatment for gastroparesis, although there is a 
need for further research in patients with evidence of 
pyloric spasms.3,17
Gastric Electrical Stimulation (GES)
GES Enterra™ therapy, implanted laparoscopically, 
is a tool for treating gastroparesis, improving gastric 
emptying and symptoms.7 The illustration scheme of 
the device for GES, two leads inserted through the 
gastric serosa with a distal needle so it is not insulated, 
the electrode part is located in the muscle layer and 
fixed by the anchors and clips. Lead is connected to 
the impulse generator connector block (Figure 3).10
GES provides high frequency (several times higher 
than the intrinsic electrical frequency of the stomach) 
electrical stimulation of lower energy to the stomach. 
Complications from this tool such as local infection 
or migration, as well as surgical complications can 
occur in up to 10% of implanted patients. There is no 
consensus or specific guidance on patient selection 
(eg, therapeutic failure, or malnutrition) for GES use. 
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GES may be considered for patients with refractory 
symptoms, particularly nausea and vomiting.3
The first open labeled study showed improvements 
in specific and global gastroparesis symptoms as well 
as improvements in gastric emptying. A double-blind, 
randomized crossover study reported improved weekly 
frequency of vomiting and quality of life in diabetic 
gastroparesis and across patient groups, but not in 
the idiopathic gastroparesis subgroup. A recent meta-
analysis of GES showed similar results and identified 
diabetic gastroparesis patients as being most responsive 
to GES, both subjectively and objectively, while the 
idiopathic gastroparesis subgroup and postoperative 
gastroparesis were less responsive.3
Several predictors for better clinical response to 
GES have recently been identified, particularly the 
etiology of diabetes and nausea and vomiting as the 
main symptoms. However, the individual response 
to GES remains unpredictable. The GES working 
mechanism is also poorly understood. The stimulation 
parameters received in clinical practice do not regulate 
the slow-wave activity of the stomach and have an 
inconsistent effect on gastric emptying. Despite 
these limitations, GES has remained very helpful in 
interventions in some patients with severe gastroparesis 
who failed to respond to medical therapy.18
Surgical Therapy
In patients with significant upper gastrointestinal 
abnormalities, gastrostomy surgery, with or 
without enterostomy ventilation, reduces the rate of 
hospitalization fivefold during the year following 
installation. The results of endoscopic ventilation 
(percutaneous endoscopic gastrostomy and direct 
percutaneous endoscopic jejunostomy) on nutritional 
outcomes and symptoms of gastroparesis have not been 
studied and remain unclear. In open label studies, the 
patient experienced marked improvement in symptoms, 
weight was maintained, and symptoms decreased up to 
3 years post gastrostomy ventilation. It is assumed that 
the same result occurs with percutaneous endoscopic 
gastrostomy, although this is not proven.3
Several types of surgical interventions have 
been tried for the treatment of gastroparesis: 
gastrojejunostomi, pyloromyotomi, and subtotal or 
complete gastrectomy. A recent study reported on 
a series of 28 patients with gastroparesis in which 
pyloroplasty resulted in symptom improvement, with a 
significant increase in gastric emptying and a reduction 
in the need for prokinetic therapy when followed for 
3 months postoperatively. It is not clear whether the 
efficacy of pyloroplasty depends on the function of the 
remaining antral motors; therefore, in some diabetics 
included in this series, there is no significant increase 
in gastric emptying, and further studies with longer 
follow-up are needed to determine the overall efficacy 
and optimal candidate for pyloroplasty in the treatment 
of gastroparesis. Pyloroplasty can relieve symptoms of 
gastroparesis and is often combined with the placement 
of a jejunal tube to support the nutrients.3
Complete or subtotal gastrectomy is applied mostly 
to gastroparesis which occurs after gastric surgery 
for peptic ulcer disease; the experience of the tertiary 
referral center shows that, in carefully selected patients, 
major gastric surgery can reduce vomiting due to severe 
gastroparesis and improve quality of life in seriously 
affected patients where the risk of subsequent renal 
failure is high and where life expectancy is poor. 
Figure 3. GES: Generator impuls (Enterra, Medtronic, Minneapolis, Minnesota, USA) and lead10
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The usefulness of complete or subtotal gastrectomy 
in patients with intact gastroparesis is not favorable.3
In a study by Papasavas et al, none of the patients 
required prokinetic therapy after surgery and each 
person had significant symptom improvement. More 
importantly, this study found that Roux-en-Y gastric 
bypass (RYGB) is a safe surgical procedure for 
obese patients. The results of this study indicate that 
gastroparesis is believed to cause patients becoming 
underweight, may appear in morbid obese patients and 
may be treated with RYGB.19
Complementary and Alternative Treatment 
Like many chronic conditions which are poorly 
understood, patients may seek alternative therapies. 
These could include: diet manipulation, physical 
training modalities (autogenic retraining as developed 
by NASA for space motion sickness), and therapies 
such as acupuncture. Dietary manipulation has been 
discussed above. The use of autonomic retraining in 
a series using NASA technology showed that patients 
with more intact autonomic nervous system activity 
respond better than patients whose autonomic function 
is more disturbed. Other therapies, such as acupuncture, 
have been tried in a more systematic way than other 
alternative therapies of gastroparesis. Several recent 
studies, including one single blinded study with false 
treatment control, have shown that acupuncture may 
be beneficial in gastroparesis.3
which require medical personnels’ skills. Persistent 
nausea and vomiting are one of the main symptoms 
of gastroparesis. Various diagnostic tests can be 
customized to the patient's condition and needs.
Comprehensive gastroparesis management, which 
involves team, not only gastroenterologists, and patient 
is required to achieve the best outcome. Management 
guideline can be applied consistently, without ignoring 
patient's wills.
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